Ms. Suzanne McGurn joined CADTH in July 2020 as its President and Chief Executive Officer. She brings to the role a deep understanding of the complex issues surrounding the management of pharmaceuticals, medical devices, and clinical interventions in Canadian health systems.
Prior to joining CADTH, Ms. McGurn’s distinguished career spanned clinical practice, patient support, and senior roles in government. Within the Ontario Ministry of Health, she served as the Assistant Deputy Minister of the Drugs and Devices Division and the Executive Officer of the Ontario Public Drug Programs. She also led the implementation of the pan-Canadian Pharmaceutical Alliance and served as its first chair.
Ms. McGurn holds both a Bachelor of Nursing Sciences and a Master of Public Administration from Queen’s University.
Agenda: Day 1 Oct 6, 2020
FIRESIDE CHAT: CADTH UPDATE
Learning from the COVID-19 Pandemic – How can it Guide Navigation in the Future for a Successful Submission the First Time Around
Accurately interpreting the impact of these learnings is fundamental to your company’s bottom line. Source intelligence to:
- Gain a comprehensive understanding of the information requirements for drug submissions to CADTH.
- Adopt best practices to better manage your product submissions under the revised process.
- Navigate the changes seamlessly and efficiently.
Position your product for a successful submission through the updated CADTH review process.
Agenda: Day 2 Oct 7, 2020